Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Phase 1 Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of MEDI9253, a Recombinant Newcastle Disease Virus Encoding Interleukin-12, in Combination With Durvalumab in Participants With Select Advanced/Metastatic Solid Tumors

NCT04613492 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT04613492
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04613492 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Phase 1 Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of MEDI9253, a Recombinant Newcastle Disease Virus Encoding Interleukin-12, in Combination With Durvalumab in Participants With Select Advanced/Metastatic Solid Tumors
Lead sponsor
AstraZeneca
Phase
Phase 1
Overall status
Terminated
Start date
December 2, 2020
Completion date
May 31, 2024
Enrollment
40 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

solid tumors